Sugi Predict

Sugi Predict / Compounds / SCHEMBL4051391

SCHEMBL4051391

SCHEMBL4051391

COc1cccc(-n2nc(C)cc2NC(=O)Nc2cccc(Cl)c2Cl)c1

nearest known ligand 0.77

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 13/20 0.77
▸ ABL1 P00519 1/20 0.58
▸ ABL2 P42684 1/20 0.58
▸ MAPK8 P45983 1/20 0.58
▸ MAPK11 Q15759 1/20 0.58
▸ NTRK1 P04629 5/20 0.56
▸ RAF1 P04049 1/20 0.55
▸ BRAF P15056 1/20 0.55
▸ EPHB2 P29323 1/20 0.55
▸ MAPT P10636 2/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2083892 0.87 MAPK14 (1.00) MAPK14ABL1ABL2MAPK8MAPK11
SCHEMBL13576980 0.86 MAPK14 (0.72) MAPK14ABL1ABL2MAPK8MAPK11
SCHEMBL4300506 0.84 MAPK14 (0.67) MAPK14ABL1ABL2MAPK8MAPK11
SCHEMBL4054955 0.83 MAPK14 (0.55) MAPK14ABL1ABL2MAPK8MAPK11
SCHEMBL4049965 0.82 KCNJ6 (0.67) MAPK14MAPK11NTRK1MAPTNPSR1
SCHEMBL4049267 0.82 MAPT (0.78) MAPK14MAPK11NTRK1BRAFMAPT
SCHEMBL4295130 0.81 MAPK14 (0.61) MAPK14ABL1ABL2MAPK8MAPK11
SCHEMBL4051361 0.80 MAPK14 (0.57) MAPK14ABL1ABL2MAPK8MAPK11
SCHEMBL2083472 0.79 MAPK14 (1.00) MAPK14ABL1ABL2MAPK8MAPK11
SCHEMBL4054036 0.78 KCNJ6 (0.61) MAPK14MAPK11NTRK1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
EP-1836173-A4 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2009-07-08 — — EP disclosed
EP-1836173-A2 ANTI-INFLAMMATORY MEDICAMENTS Deciphera Pharmaceuticals, LLC (US) 2007-09-26 — — EP disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
WO-2006081034-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 MAPK14 80/4885ABL1 2/4885ABL2 1/4885
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MAPK14 29/4885ABL1 174/4885ABL2 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.